Market Place
Sourcing Support
DermBiont Announces SM-020 As Lead Indication For Basal Cell Carcinoma Treatment
15 Aug 2024 //
BUSINESSWIRE
DermBiont Announces Pipeline Update for Targeted Topical Therapeutics
22 Feb 2024 //
BUSINESSWIRE
DermBiont raises $35.2M Series B to advance two dermatological drugs through PII
25 Oct 2023 //
ENDPTS
DermBiont Announces First Close of $35.2 Million in a Series B Financing
24 Oct 2023 //
BUSINESSWIRE
DermBiont Announces Positive Data from a Phase 2 Trial Treating Solar Lentigo
30 May 2023 //
BUSINESSWIRE
DermBiont Presents PII Trial Data Treating Seborrheic Keratosis with SM-020
22 Mar 2023 //
BUSINESSWIRE
DermBiont`s topical gel hits goal in benign skin growth phase 2
28 Jun 2022 //
FIERCEPHARMA
DermBiont Announces Positive PII Trial Data in Seborrheic Keratosis with SM-020
23 Jun 2022 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.